These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 35076580)

  • 1. RhoA, Claudin 18, and c-MET in Gastric Cancer: Clinicopathological Characteristics and Prognostic Significance in Curative Resected Patients.
    Pereira MA; Ramos MFKP; Dias AR; Cardili L; Ribeiro RRE; de Castria TB; Zilberstein B; Nahas SC; Ribeiro U; de Mello ES
    Med Sci (Basel); 2021 Dec; 10(1):. PubMed ID: 35076580
    [No Abstract]   [Full Text] [Related]  

  • 2. CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer.
    Wang C; Wang Y; Chen J; Wang Y; Pang C; Liang C; Yuan L; Ma Y
    BMC Gastroenterol; 2023 Aug; 23(1):283. PubMed ID: 37582713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Correlation Between RhoA Expression and Clinicopathological Characteristics in Gastric Cancer Patients After Curative Surgery.
    Huang KH; Lan YT; Chen MH; Chao Y; Lo SS; Li AF; Wu CW; Chiou SH; Yang MH; Shyr YM; Fang WL
    World J Surg; 2015 Sep; 39(9):2289-99. PubMed ID: 26013205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of the potential therapeutic target claudin-18.2 is frequently decreased in gastric cancer: results from a large Caucasian cohort study.
    Dottermusch M; Krüger S; Behrens HM; Halske C; Röcken C
    Virchows Arch; 2019 Nov; 475(5):563-571. PubMed ID: 31332522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer.
    Jia K; Chen Y; Sun Y; Hu Y; Jiao L; Ma J; Yuan J; Qi C; Li Y; Gong J; Gao J; Zhang X; Li J; Zhang C; Shen L
    BMC Med; 2022 Jul; 20(1):223. PubMed ID: 35811317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
    He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
    World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Claudin-18.2 testing and its impact in the therapeutic management of patients with gastric and gastroesophageal adenocarcinomas: A literature review with expert opinion.
    Angerilli V; Ghelardi F; Nappo F; Grillo F; Parente P; Lonardi S; Luchini C; Pietrantonio F; Ugolini C; Vanoli A; Fassan M
    Pathol Res Pract; 2024 Feb; 254():155145. PubMed ID: 38277741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological significance and immunotherapeutic outcome of claudin 18.2 expression in advanced gastric cancer: A retrospective study.
    Qi C; Chong X; Zhou T; Ma M; Gong J; Zhang M; Li J; Xiao J; Peng X; Liu Z; Li Z; Shen L; Zhang X
    Chin J Cancer Res; 2024 Feb; 36(1):78-89. PubMed ID: 38455365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent RhoGAP gene fusion CLDN18-ARHGAP26 promotes RHOA activation and focal adhesion kinase and YAP-TEAD signalling in diffuse gastric cancer.
    Zhang F; Sahu V; Peng K; Wang Y; Li T; Bala P; Aitymbayev D; Sahgal P; Schaefer A; Der CJ; Ryeom S; Yoon S; Sethi N; Bass AJ; Zhang H
    Gut; 2024 Jul; 73(8):1280-1291. PubMed ID: 38621923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colitis-associated colorectal adenocarcinomas frequently express claudin 18 isoform 2: implications for claudin 18.2 monoclonal antibody therapy.
    Iwaya M; Hayashi H; Nakajima T; Matsuda K; Kinugawa Y; Tobe Y; Tateishi Y; Iwaya Y; Uehara T; Ota H
    Histopathology; 2021 Aug; 79(2):227-237. PubMed ID: 33590909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole-transcriptome sequencing in advanced gastric or gastroesophageal cancer: A deep dive into its clinical potential.
    Hashimoto T; Nakamura Y; Mishima S; Nakayama I; Kotani D; Kawazoe A; Kuboki Y; Bando H; Kojima T; Iida N; Shibuki T; Imai M; Fujisawa T; Nagamine M; Sakamoto N; Kuwata T; Yoshino T; Shitara K
    Cancer Sci; 2024 May; 115(5):1622-1633. PubMed ID: 38429886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scoring systems for PD-L1 expression and their prognostic impact in patients with resectable gastric cancer.
    Pereira MA; Ramos MFKP; Dias AR; Ribeiro R; Cardili L; Zilberstein B; Cecconello I; Ribeiro U; de Mello ES; de Castria TB
    Virchows Arch; 2021 Jun; 478(6):1039-1048. PubMed ID: 33098489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-1303 targets claudin-18 gene to modulate proliferation and invasion of gastric cancer cells.
    Zhang SJ; Feng JF; Wang L; Guo W; Du YW; Ming L; Zhao GQ
    Dig Dis Sci; 2014 Aug; 59(8):1754-63. PubMed ID: 24647998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. c-Met-dependent phosphorylation of RhoA plays a key role in gastric cancer tumorigenesis.
    Liu J; Li S; Chen S; Chen S; Geng Q; Xu D
    J Pathol; 2019 Sep; 249(1):126-136. PubMed ID: 31056743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of Claudin18.2 expression with clinicopathological characteristics and prognosis in gastric cancer.
    Tao D; Guan B; Li Z; Jiao M; Zhou C; Li H
    Pathol Res Pract; 2023 Aug; 248():154699. PubMed ID: 37487317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of tumor heterogeneity of p-Smad2 and c-Met in HER2-positive gastric carcinoma with lymph node metastasis.
    Tsujio G; Maruo K; Yamamoto Y; Sera T; Sugimoto A; Kasashima H; Miki Y; Yoshii M; Tamura T; Toyokawa T; Tanaka H; Muguruma K; Ohira M; Yashiro M
    BMC Cancer; 2022 Jun; 22(1):598. PubMed ID: 35650563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer.
    Kubota Y; Kawazoe A; Mishima S; Nakamura Y; Kotani D; Kuboki Y; Bando H; Kojima T; Doi T; Yoshino T; Kuwata T; Shitara K
    ESMO Open; 2023 Feb; 8(1):100762. PubMed ID: 36610262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Prognostic Significance of c-MET and EGFR Overexpression in Resected Gastric Adenocarcinomas.
    Paliga A; Marginean H; Tessier-Cloutier B; Purgina B; Jonker D; Marginean EC
    Am J Clin Oncol; 2017 Dec; 40(6):543-551. PubMed ID: 26125303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Claudin-18 status and its correlation with HER2 and PD-L1 expression in gastric cancer with peritoneal dissemination.
    Ogawa H; Abe H; Yagi K; Seto Y; Ushiku T
    Gastric Cancer; 2024 Jul; 27(4):802-810. PubMed ID: 38724721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastric cancer molecular classification based on immunohistochemistry and in situ hybridization: Analysis in western patients after curative-intent surgery.
    Ramos MFKP; Pereira MA; de Mello ES; Cirqueira CDS; Zilberstein B; Alves VAF; Ribeiro-Junior U; Cecconello I
    World J Clin Oncol; 2021 Aug; 12(8):688-701. PubMed ID: 34513602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.